Proteon Therapeutics

Proteon Therapeutics

File:Proteon Therapeutics logo.png

Logo of Proteon Therapeutics

Proteon Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics to address significant unmet needs in patients with kidney and vascular diseases. The company is known for its innovative approach to treating conditions that affect blood vessels, particularly in the context of chronic kidney disease and hemodialysis.

History

Proteon Therapeutics was founded with the mission to improve the lives of patients suffering from vascular diseases. The company has been at the forefront of developing therapies that target the underlying causes of these conditions, aiming to enhance the quality of life and outcomes for patients.

Research and Development

Proteon Therapeutics has focused its research efforts on the development of a proprietary enzyme, vonapanitase, which is designed to improve vascular access outcomes for patients undergoing hemodialysis. Vonapanitase is a recombinant human elastase that works by cleaving elastin fibers in the vessel wall, potentially reducing vessel narrowing and improving blood flow.

Vonapanitase

Vonapanitase is the lead product candidate of Proteon Therapeutics. It is intended for use in patients with chronic kidney disease who require arteriovenous fistula creation for hemodialysis. The enzyme is applied locally to the external surface of the blood vessel during surgery, with the goal of improving the patency and function of the arteriovenous fistula.

Clinical Trials

Proteon Therapeutics has conducted several clinical trials to evaluate the safety and efficacy of vonapanitase. These trials have been designed to assess the ability of the enzyme to improve vascular access outcomes, reduce the need for additional interventions, and enhance the overall dialysis experience for patients.

Impact on Vascular Access

The development of vonapanitase represents a significant advancement in the field of vascular access for hemodialysis patients. By potentially improving the longevity and functionality of arteriovenous fistulas, vonapanitase may reduce the burden of repeated surgical procedures and interventions, leading to better patient outcomes and reduced healthcare costs.

Related Pages

• Chronic kidney disease
• Hemodialysis
• Arteriovenous fistula
• Biopharmaceutical